Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a research report issued on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The company has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 52 week low of $0.01 and a 52 week high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.